Journal home
Advance online publication
Current issue
Archive
Press releases
Supplements
Focuses
Conferences
Guide to authors
Online submissionOnline submission
Permissions
For referees
Free online issue
Contact the journal
Subscribe
Advertising
work@npg
naturereprints
About this site
For librarians
 
NPG Resources
Bioentrepreneur
Nature Reviews Drug Discovery
Nature
Nature Medicine
Nature Genetics
Nature Reviews Genetics
Nature Methods
Nature Chemical Biology
news@nature.com
Clinical Pharmacology & Therapeutics
Nature Conferences
NPG Subject areas
Biotechnology
Cancer
Chemistry
Clinical Medicine
Dentistry
Development
Drug Discovery
Earth Sciences
Evolution & Ecology
Genetics
Immunology
Materials Science
Medical Research
Microbiology
Molecular Cell Biology
Neuroscience
Pharmacology
Physics
Browse all publications
Article
Nature Biotechnology  21, 1328 - 1335 (2003)
Published online: 12 October 2003; | doi:10.1038/nbt887

E3 gene manipulations affect oncolytic adenovirus activity in immunocompetent tumor models

Yaohe Wang1, Gunnel Hallden1, Richard Hill1, Arthi Anand1, Ta-Chiang Liu1, Jennelle Francis1, Gabriel Brooks1, Nick Lemoine1 & David Kirn1, 2

1  Viral and Genetic Therapy Program, Cancer Research UK and Imperial College School of Medicine, Hammersmith Hospital, London, UK.

2  Present address: Department of Pharmacology, Oxford University Medical School, Oxford, UK.

Correspondence should be addressed to David Kirn davidhkirn@sbcglobal.net
Oncolytic replication-selective adenoviruses constitute a rapidly growing therapeutic platform for cancer. However, the role of the host immune response and the E3 immunoregulatory genes of the human adenovirus were unknown until now. We identified four mouse carcinoma lines of variable permissivity for adenoviral gene expression, cytopathic effects and/or burst size. To determine E3 gene effects in immunocompetent tumor-bearing hosts, we injected tumors with one of three adenoviruses: Ad5 (E3 wild type), dl309 (del. E3 10.4/14.5, 14.7 kDa) or dl704 (del. E3 gp19 kDa). Compared with Ad5 and dl704, dl309 was cleared much more rapidly and/or its activity was lower in all four models. Intratumoral injection with dl309 resulted in markedly greater macrophage infiltration and expression of both tumor necrosis factor and interferon-bold gamma. Adenovirus replication, CD8+ lymphocyte infiltration and efficacy were similar upon intratumoral injection with either dl704 or Ad5. E3-dependent differences were not evident in athymic mice. These findings have important implications for the design of oncolytic adenoviruses and may explain the rapid clearance of E3-10.4/14.5,14.7-deleted adenoviruses in patients.

MORE ARTICLES LIKE THIS
These links to content published by NPG are automatically generated

REVIEWS
Adenoviral vectors: Systemic delivery and tumor targeting
Cancer Gene Therapy Reviews (01 Dec 2002)
Replication-selective oncolytic adenoviruses: virotherapy aimed at genetic targets in cancer
Oncogene Reviews (08 Feb 2001)
 See all 3 matches for Reviews

RESEARCH
An adenovirus E1A mutant that demonstrates potent and selective systemic anti-tumoral efficacy
Nature Medicine Article (01 Oct 2000)
Re-engineering adenovirus regulatory pathways to enhance oncolytic specificity and efficacy
Nature Biotechnology Research (01 Nov 2001)
A novel hypoxia-inducible factor (HIF) activated oncolytic adenovirus for cancer therapy
Oncogene Original Article (10 Apr 2003)
 See all 9 matches for Research

 Top
Abstract
Previous | Next
Table of contents
Full textFull text
Download PDFDownload PDF
Send to a friendSend to a friend
Save this linkSave this link

naturejobs

Figures & Tables
Export citation
natureproducts

Search buyers guide:

 
ADVERTISEMENT
 
Nature Biotechnology
ISSN: 1087-0156
EISSN: 1546-1696
Journal home | Advance online publication | Current issue | Archive | Press releases | Supplements | Focuses | Conferences | For authors | Online submission | Permissions | For referees | Free online issue | About the journal | Contact the journal | Subscribe | Advertising | work@npg | naturereprints | About this site | For librarians
Nature Publishing Group, publisher of Nature, and other science journals and reference works©2003 Nature Publishing Group | Privacy policy